Emerging anti-spike monoclonal antibodies against SARS-CoV-2.
Eloy E OrdayaRaymund R RazonablePublished in: Expert opinion on biological therapy (2024)
Although the available data of novel mAbs holds promise, we anticipate that these agents will face similar challenges encountered by prior authorized agents, including the continued evolution of SARS-CoV-2 and emergence of new escape mutations. Strategies to potentially mitigate this are discussed. Based on prior successful experience, immunocompromised patients will certainly benefit from the utilization of mAbs for the prevention and treatment of COVID-19; thus, we need to design potential interventions to ensure the sustained activity of these agents.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- ejection fraction
- newly diagnosed
- coronavirus disease
- big data
- prognostic factors
- peritoneal dialysis
- electronic health record
- patient reported outcomes
- risk assessment
- artificial intelligence
- respiratory failure
- combination therapy
- patient reported
- smoking cessation
- data analysis